EUVIMEDOpdag EUVIMED
Crossref

A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system

Advaitaa Ravipati iD, Tejus Pradeep, Antonella Tosti

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.17014 ↗

At a glance

Journal article in International Journal of Dermatology, 2024. Written by Advaitaa Ravipati and 2 co-authors. Institution: Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. Major MEDLINE topics: Alopecia Areata. Cited 6 times so far (Crossref); 26 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Alopecia areata (AA) is an autoimmune condition that leads to patchy, nonscarring hair loss. Its etiology remains unknown; the condition can be debilitating for patients, impacting their psychosocial wellbeing. Various triggers have been reported, ranging from genetic predisposition and infections to environmental factors. Medications have also been thought to be an inciting factor in AA.

Methods

Using the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS), all cases reporting AA as an adverse event were used to capture associated medications and patient characteristics.

Results

There were 1,331 AA cases reported as an adverse event with medication use. Monoclonal antibodies accounted for 6 out of the top 10 drugs associated with the highest number of AA cases. Males were more likely to report AA when taking adalimumab (OR: 1.79, P = 0.04) and dupilumab (OR: 2.56, P = 0.03) compared to females. Individuals between 42 and 64 years old accounted for 46.7% of AA cases. Lastly, females in older age groups showed greater odds of developing AA compared to males (OR: 1.03, P < 0.01).

Conclusions

Based on the FAERS, there has been a steady rise in AA cases, and monoclonal antibodies were the most frequently cited medication class tied to AA. With a dearth of literature on triggers and patient demographics, we sought to describe features of AA cases that could increase awareness and be used to improve future clinical outcomes in patients.

Subjects

MeSH terms (MEDLINE)

Alopecia AreataUnited StatesMaleFemaleHumansAgedAdultMiddle AgedCross-Sectional StudiesUnited States Food and Drug AdministrationAlopeciaAntibodies, Monoclonal

Substances

Antibodies, Monoclonal

Authors and institutions

  • Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USA.

ORCID profiles: Advaitaa Ravipati

Cite

APA

Ravipati, A., Pradeep, T., & Tosti, A. (2024). A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system. International Journal of Dermatology. https://doi.org/10.1111/ijd.17014

Vancouver

Ravipati A, Pradeep T, Tosti A. A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system. International Journal of Dermatology. 2024. doi:10.1111/ijd.17014

BibTeX
@article{Ravipati2024,
  author = {Ravipati, Advaitaa and Pradeep, Tejus and Tosti, Antonella},
  title = {A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.17014}
}
Start for free →